See more : Cachet Pharmaceutical Co., Ltd. (002462.SZ) Income Statement Analysis – Financial Results
Complete financial analysis of PRISM BioLab Co.,LTD (206A.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PRISM BioLab Co.,LTD, a leading company in the Biotechnology industry within the Healthcare sector.
- Quebec Precious Metals Corporation (CJCFF) Income Statement Analysis – Financial Results
- Integral Diagnostics Limited (IDX.AX) Income Statement Analysis – Financial Results
- Esquire Financial Holdings, Inc. (ESQ) Income Statement Analysis – Financial Results
- Volpara Health Technologies Limited (VHT.AX) Income Statement Analysis – Financial Results
- Novonix Limited (NVNXF) Income Statement Analysis – Financial Results
PRISM BioLab Co.,LTD (206A.T)
About PRISM BioLab Co.,LTD
PRISM Pharma Co., Ltd. operates as a pharmaceutical company that focuses on discovery and development of small molecules to modulate protein-protein interactions. It utilizes protein secondary structure mimetic library, which modulates intracellular protein and protein interactions. The firm develops an anti-cancer drug CP/Catenin inhibitor PRI-724 that acts on both cancer cells and cancer stem cells that can switch from proliferation to differentiation. The company was founded by Hiroyuki Kouji on November 2, 2006 and is headquartered in Fujisawa, Japan.
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 305.62M | 112.93M | 554.40M |
| Cost of Revenue | 145.08M | 32.62M | 19.26M |
| Gross Profit | 160.54M | 80.31M | 535.14M |
| Gross Profit Ratio | 52.53% | 71.11% | 96.53% |
| Research & Development | 0.00 | 338.73M | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 238.08M | 0.00 |
| Other Expenses | 942.93M | 0.00 | -1.50M |
| Operating Expenses | 942.93M | 577.17M | 468.45M |
| Cost & Expenses | 1.09B | 609.79M | 487.71M |
| Interest Income | 356.00K | 19.00K | 21.00K |
| Interest Expense | 13.50M | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 8.74M | 1.21M |
| EBITDA | -782.39M | -488.13M | 67.89M |
| EBITDA Ratio | -256.00% | -432.26% | 13.06% |
| Operating Income | -782.39M | -496.87M | 66.68M |
| Operating Income Ratio | -256.00% | -439.99% | 12.03% |
| Total Other Income/Expenses | -265.81M | -28.84M | 7.48M |
| Income Before Tax | -1.05B | -525.70M | 74.16M |
| Income Before Tax Ratio | -342.98% | -465.53% | 13.38% |
| Income Tax Expense | 1.31M | 1.21M | 1.19M |
| Net Income | -1.05B | -526.91M | 72.96M |
| Net Income Ratio | -343.40% | -466.60% | 13.16% |
| EPS | -33.47 | -14.90 | 0.00 |
| EPS Diluted | -33.47 | -19.09 | 0.00 |
| Weighted Avg Shares Out | 31.35M | 35.35M | 0.00 |
| Weighted Avg Shares Out (Dil) | 31.35M | 27.60M | 0.00 |
Source: https://incomestatements.info
Category: Stock Reports